Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
Open accessAbstract
Background: Although a number of studies have reported acquired drug resistance due to administration of epidermal growth factor receptor antibody inhibitors, the underlying causes of this phenomenon remain unclear. Case presentation: Here we report a case of a 75-year-old man with liver metastasis at 3 years after a successful transverse colectomy to treat KRAS wild-type colorectal cancer. While initial administration of epidermal growth factor receptor inhibitors proved effective, continued use of the same treatment resulted in new peritoneal seeding. An acquired KRAS mutation was found in a resected tissue specimen from one such area. This mutation, possibly caused by administration of epidermal growth factor receptor inhibitors, appears to have conferred drug resistance. Conclusion: The present findings suggest that administration of epidermal growth factor receptor inhibitors results in an acquired KRAS mutation that confers drug resistance.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
KRAS point mutations and gene copy number gains are responsible for acquired resistance in 38-60% of patients who relapse on cetuximab or panitumumab.
“KRAS point mutations and gene copy number gains are responsible not only for primary but also for acquired resistance in 38–60 % of patients who relapse on cetuximab or panitumumab [37-39].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704 · see citing works
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,063 · see citing works
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · see citing works
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · see citing works
Liu, B., Ying, J., Luo, C., Xu, Q., Zhu, L., & Zhong, H. (2012) · Hepatogastroenterology · doi:10.5754/hge11893 · Cited by 1,338 · see citing works
Montagut, C., Dalmases, A., Bellosillo, B., Crespo, M., Pairet, S., Iglesias, M., Salido, M., Gallen, M., Marsters, S., Tsai, S. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2609 · Cited by 513 · see citing works
Knijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291 · see citing works
Watanabe, T., Kobunai, T., Yamamoto, Y., Matsuda, K., Ishihara, S., Nozawa, K., Iinuma, H., Shibuya, H., & Eshima, K. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821d37a3 · Cited by 82 · see citing works
The road to resistance: EGFR mutation and cetuximab
Bardelli, A., & Janne, P. A. (2012) · Nature Medicine · doi:10.1038/nm.2646 · Cited by 71 · see citing works
Han, C., Li, F., Ma, J., & Zou, H. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.732159 · Cited by 71 · see citing works
Bouchahda, M., Karaboué, A., Saffroy, R., Innominato, P. F., Gorden, L. D., Guettier, C., Adam, R. A., & Lévi, F. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1298-9 · Cited by 64 · see citing works
Li, Z., Jin, K., Lan, H., & Teng, L. (2011) · PubMed · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Leto, S. M., & Trusolino, L. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1161-2 · Cited by 87 · see citing works
Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer
Koulis, C., Yap, R. J., Engel, R. M., Jardé, T., Wilkins, S., Solon, J. G., Shapiro, J. D., Abud, H. E., & McMurrick, P. J. (2020) · Cancers · doi:10.3390/cancers12040812 · Cited by 60 · see citing works
Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities
Daga, A., Ansari, A., Patel, S., Mirza, S., Rawal, R., & Umrania, V. V. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.10.4147 · Cited by 47 · see citing works
ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia
Wang, Y., Skibbe, J. R., Hu, C., Dong, L., Ferchen, K., Su, R. J., Li, C., Huang, H., Weng, H., Huang, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01913-y · Cited by 36 · see citing works
Khelwatty, S. A., Essapen, S., Seddon, A. M., Fan, Z., & Modjtahedi, H. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.319 · Cited by 24 · see citing works
Chen, S., Tsai, H., Jiang, J., Sung, Y.-C., Huang, C.-W., Yeh, Y., Chen, L., & Wang, J. (2019) · BMC Cancer · doi:10.1186/s12885-019-5826-7 · Cited by 6 · see citing works
Resistance of Colorectal Tumors to Anti-EGFR Antibodies
Trusolino, L., & Leto, S. M. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_1 · Cited by 2 · see citing works
When to screen and not to screen
Cruickshanks, N. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.27741 · Cited by 1 · see citing works
(2015) · Reactions Weekly · doi:10.1007/s40278-015-2125-1
- Authors
- Osumi, H., Matsusaka, S., Shinozaki, E., Suenaga, M., Mingyon, M., Saiura, A., Ueno, M., Mizunuma, N., & Yamaguchi, T.
- Affiliations
- The Cancer Institute Hospital (JP)
- Corresponding author
- Matsusaka, Satoshi
- Venue
- BMC Research Notes
- Published
- 2013-12
- Volume
- 6
- Issue
- 1
- Pages
- 508-508
- ISSN
- 1756-0500 (ISSN-L)
- PMC
- PMC3866299
- OpenAlex
- W2052883113
- Cited by
- 9
- References
- 12
- Citations by year
- 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 3 · 2014: 2
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Research Notes (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- acquired drug resistance, KRAS mutation, cetuximab, EGFR inhibitors, colorectal cancer, liver metastasis, peritoneal seeding, anti-EGFR antibody therapy
- MeSH terms
- Cetuximab, Aged, Antineoplastic Agents, Humans, Male, Mutation, Genes, ras, Colorectal Neoplasms, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
